Therefore, the health system is forced to purchase cytostatics through third parties or from markets in Europe and Asia, significantly increasing costs, especially in regards to shipping and transport.
因此，卫生系统被逼通过第三方或从欧洲和亚洲市场购买细胞抑制药剂，费用大为增高，特别是在运送和运输方面。